CJC-1295 No DAC (Modified GRF 1-29) is one of the most widely investigated growth hormone-releasing hormone (GHRH) analogs in modern peptide research. PX1 Research provides analytical-grade, USA-manufactured CJC-1295 No DAC engineered specifically for rigorous in vitro assays and preclinical laboratory protocols. Every batch undergoes exhaustive third-party testing to guarantee identity, chromatographic purity, and ultra-low endotoxin levels.
CJC-1295 No DAC (Modified GRF 1-29) is one of the most widely investigated growth hormone-releasing hormone (GHRH) analogs in modern peptide research. PX1 Research provides analytical-grade, USA-manufactured CJC-1295 No DAC engineered specifically for rigorous in vitro assays and preclinical laboratory protocols. Every batch undergoes exhaustive third-party testing to guarantee identity, chromatographic purity, and ultra-low endotoxin levels.
When seeking to buy CJC-1295 No DAC online for laboratory research, qualified institutions require analytical validation, high purity (>98%), and verified lot traceability. CJC-1295 No DAC (Modified GRF 1-29) is a synthetic 29-amino-acid peptide available from PX1 Research as a lyophilized reagent with lot-specific HPLC/MS COAs and endotoxin testing for controlled in vitro and preclinical study.
Navigating the research peptide marketplace demands stringent quality verification. Academic laboratories, biotechnology firms, and institutional researchers must ensure that raw materials are free from trifluoroacetic acid (TFA) salts, heavy metals, and bacterial endotoxins that could skew cell culture dynamics or animal model data. Buying CJC-1295 No DAC directly from PX1 Research ensures access to USA-manufactured compounds backed by comprehensive analytical documentation from an independent ISO 17025 accredited laboratory.
Researchers exploring our complete research peptide catalog will find that PX1 Research maintains strict cold-chain storage and rapid logistics, dispatching orders same-day from domestic distribution nodes in California and Arizona to preserve secondary structure integrity upon arrival.
CJC-1295 No DAC, commercially and scientifically recognized as Modified GRF 1-29 (Growth Hormone-Releasing Factor 1-29), is a truncated, synthetic peptide derivative of naturally occurring GHRH (1-44). The native GHRH molecule comprises 44 amino acids, but structural activity relationship (SAR) studies determined that the N-terminal 29-amino-acid sequence retains full biological activity at the GHRH receptor.
To mitigate rapid enzymatic degradation by circulating dipeptidyl peptidase-IV (DPP-IV), four strategic amino acid substitutions were incorporated into the native sequence: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27. This modified sequence—Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2—exhibits significantly enhanced metabolic stability compared to native GHRH(1-29) while lacking the Drug Affinity Complex (DAC) maleimide conjugation group.
The absence of the DAC moiety alters the pharmacokinetic profile dramatically: CJC-1295 No DAC exhibits a half-life of approximately 30 minutes in plasma, facilitating natural, pulsatile growth hormone secretagogue responses rather than the prolonged, continuous elevation produced by its DAC-conjugated counterpart. Investigators interested in structural GHRH derivatives can compare these features against CJC-1295 DAC in controlled research models.
At the cellular level, CJC-1295 No DAC functions as a selective agonist of the growth hormone-releasing hormone receptor (GHRH-R), a Class B G-protein-coupled receptor primarily localized on somatotroph cells in the anterior pituitary gland. Binding of the peptide to GHRH-R triggers a conformational change that activates heterotrimeric Gs proteins, stimulating intracellular adenylyl cyclase activity.
This enzymatic activation converts ATP to cyclic adenosine monophosphate (cAMP), which subsequently activates protein kinase A (PKA). The PKA signaling cascade promotes intracellular calcium influx and phosphorylates transcription factors such as CREB, triggering the transcription and exocytosis of pre-stored growth hormone (GH) granules. Preclinical studies suggest that this signal transduction pathway preserves the natural, pulsatile release pattern of endogenous GH.
Downstream of pituitary GH release, circulating growth hormone acts upon hepatic GHR receptors to stimulate the synthesis and secretion of Insulin-like Growth Factor 1 (IGF-1). IGF-1 serves as the primary endocrine mediator of cell proliferation, protein synthesis, and extracellular matrix remodeling, making GHRH receptor analogs critical instruments in cellular metabolism and tissue regeneration studies.
In animal models and preclinical literature, CJC-1295 No DAC has been extensively utilized to investigate systemic metabolic regulation, skeletal muscle hypertrophy, and cellular repair processes. Rodent models receiving Modified GRF 1-29 demonstrate measurable increases in serum GH and IGF-1 levels without disrupting endogenous baseline feed-forward or negative feedback loops.
In vitro data indicate that CJC-1295 No DAC accelerates protein translation rates in cultured myoblasts and chondrocytes. Investigators studying peptides for tissue repair frequently employ Modified GRF 1-29 to measure collagen deposition rates, fibroblast proliferation, and satellite cell activation following mechanical or chemical injury.
Furthermore, preclinical research highlights the role of sustained GH/IGF-1 axis activation in lipid mobilization and glucose homeostasis. Rodent metabolic studies demonstrate that administration of GHRH secretagogues shifts substrate utilization toward fatty acid oxidation, providing valuable data for obesity, metabolic syndrome, and sarcopenia disease models.
Understanding the differences between GHRH analogs and ghrelin receptor agonists (GHRPs) is critical for experimental design. While CJC-1295 No DAC acts strictly via the GHRH receptor with a short biological half-life (~30 minutes), CJC-1295 DAC features a Lys(DAC) modification that covalently binds to serum albumin, extending its biological activity to several days and driving baseline GH elevation.
Conversely, compounds like Ipamorelin act via an entirely distinct pathway: the Growth Hormone Secretagogue Receptor (GHSR-1a or ghrelin receptor). Preclinical literature demonstrates that combining a GHRH agonist (such as CJC-1295 No DAC) with a GHRP (such as Ipamorelin) produces a synergistic elevation of GH release far exceeding the additive sum of either peptide alone. This synergy occurs because GHRH increases GH synthesis and release amplitude, while GHRPs suppress somatostatin inhibition.
Researchers evaluating these pathways often select CJC-1295 No DAC over DAC variants when the experimental protocol requires physiological, pulsatile GH spikes rather than continuous GHRH receptor occupation, minimizing the risk of receptor desensitization in long-term cellular studies.
CJC-1295 No DAC is supplied by PX1 Research as a sterile, lyophilized cake in sealed glass vials. To maintain molecular integrity, researchers must adhere to strict aseptic techniques and standardized reconstitution procedures. Lyophilized vials should be stored at -20°C prior to use, protected from light exposure.
Reconstitution should be performed using sterile laboratory-grade Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Normal Saline, depending on the requirements of the downstream in vitro or animal assay. Diluent should be introduced gently down the inner glass wall of the vial, allowing the peptide cake to dissolve without aggressive agitation or vortexing, which can disrupt delicate secondary peptide bonds.
Following reconstitution, liquid aliquots remain stable at 2°C to 8°C for up to 30 days. For long-term preservation of reconstituted solutions, sub-aliquoting into sterile polypropylene tubes and freezing at -80°C prevents repeated freeze-thaw cycles. Detailed step-by-step guidance can be accessed through our peptide reconstitution guide.
The scientific validity of preclinical research relies entirely on material purity and consistency. PX1 Research enforces rigorous quality control protocols for every lot of CJC-1295 No DAC produced in our US manufacturing facilities. We do not rely on generic manufacturer certificates; every lot is independently verified by accredited ISO 17025 laboratories.
Purity is quantified using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a minimum purity threshold of 98%. Mass identity is confirmed via Electrospray Ionization Mass Spectrometry (ESI-MS), verifying that the observed molecular mass matches the theoretical mass of Modified GRF 1-29 exactly, eliminating concerns regarding truncated fragments or deletion sequences.
In addition, all lots undergo Limulus Amebocyte Lysate (LAL) testing to confirm ultra-low endotoxin levels (<0.05 EU/mg), preventing confounding inflammatory responses in cell culture assays or preclinical animal models. Investigators can review batch-specific test results directly via our PX1 Research analytical hub.
PX1 Research is the trusted domestic source for academic institutions, contract research organizations (CROs), and independent researchers requiring top-tier peptide reagents. By standardizing manufacturing within ISO-compliant, GMP-certified domestic facilities, PX1 eliminates supply chain volatility and quality variations common with overseas importers.
We support research teams of all sizes by offering scalable supply options, from individual laboratory research units to bulk production volumes available through our wholesale lab accounts. Every order is backed by full lot traceability, transparent documentation, and direct technical customer support.
When you buy CJC-1295 No DAC online from PX1 Research, your order is processed immediately and shipped same-day (Monday through Friday) from our CA or AZ fulfillment centers, ensuring rapid domestic transit and temperature-managed delivery.
What is the difference between CJC-1295 No DAC and CJC-1295 with DAC?
CJC-1295 No DAC (Modified GRF 1-29) lacks the Drug Affinity Complex (DAC) maleimide reactive group. As a result, CJC-1295 No DAC has a biological half-life of approximately 30 minutes, creating natural pulsatile peaks in growth hormone secretion. CJC-1295 with DAC binds covalently to serum albumin, extending its half-life to several days and resulting in sustained GH elevation.
What purity grade is guaranteed when I buy CJC-1295 No DAC from PX1 Research?
Every lot of CJC-1295 No DAC from PX1 Research is verified via RP-HPLC to meet or exceed 98% purity. Detailed Certificates of Analysis (COAs) including HPLC chromatograms and mass spectrometry reports are available for every lot.
How is CJC-1295 No DAC tested for bacterial endotoxins?
PX1 Research utilizes standard Limulus Amebocyte Lysate (LAL) assays to measure endotoxin levels. All batches must test below strict limits (<0.05 EU/mg) to ensure suitability for sensitive cell culture and preclinical animal models.
What solvent should be used to reconstitute CJC-1295 No DAC for laboratory assays?
CJC-1295 No DAC is typically reconstituted using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS), depending on the specific requirements of the in vitro assay or preclinical trial.
How should CJC-1295 No DAC be stored upon arrival at the laboratory?
Lyophilized CJC-1295 No DAC should be stored at -20°C for long-term stability. Once reconstituted, liquid aliquots should be refrigerated at 2°C to 8°C and used within 30 days, or sub-aliquoted and frozen at -80°C to prevent freeze-thaw degradation.
Why is CJC-1295 No DAC frequently combined with Ipamorelin in research protocols?
In preclinical literature, combining a GHRH analog (CJC-1295 No DAC) with a GHRP/ghrelin agonist (Ipamorelin) demonstrates a synergistic effect on pituitary GH release. GHRH stimulates GH synthesis and release, while Ipamorelin inhibits somatostatin tone, maximizing total secretory output.
Where does PX1 Research manufacture and ship CJC-1295 No DAC?
PX1 Research manufactures peptides in USA-based, GMP-compliant facilities. Orders are fulfilled and shipped same-day (M-F) directly from domestic distribution centers located in California and Arizona.
Is CJC-1295 No DAC approved for human consumption or therapeutic use?
No. CJC-1295 No DAC supplied by PX1 Research is strictly designated for laboratory research use only (in vitro and preclinical animal research). It is not for human or veterinary diagnostic, therapeutic, or clinical applications.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.